Cargando…
Therapeutic Potentials of Reducing Liver Fat in Non-Alcoholic Fatty Liver Disease: Close Association with Type 2 Diabetes
Nonalcoholic fatty liver disease (NAFLD), the most widespread chronic liver disease worldwide, confers a significant burden on health systems and leads to increased mortality and morbidity through several extrahepatic complications. NAFLD comprises a broad spectrum of liver-related disorders, includ...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141666/ https://www.ncbi.nlm.nih.gov/pubmed/37110175 http://dx.doi.org/10.3390/metabo13040517 |
_version_ | 1785033434575405056 |
---|---|
author | Tsamos, Georgios Vasdeki, Dimitra Koufakis, Theocharis Michou, Vassiliki Makedou, Kali Tzimagiorgis, Georgios |
author_facet | Tsamos, Georgios Vasdeki, Dimitra Koufakis, Theocharis Michou, Vassiliki Makedou, Kali Tzimagiorgis, Georgios |
author_sort | Tsamos, Georgios |
collection | PubMed |
description | Nonalcoholic fatty liver disease (NAFLD), the most widespread chronic liver disease worldwide, confers a significant burden on health systems and leads to increased mortality and morbidity through several extrahepatic complications. NAFLD comprises a broad spectrum of liver-related disorders, including steatosis, cirrhosis, and hepatocellular carcinoma. It affects almost 30% of adults in the general population and up to 70% of people with type 2 diabetes (T2DM), sharing common pathogenetic pathways with the latter. In addition, NAFLD is closely related to obesity, which acts in synergy with other predisposing conditions, including alcohol consumption, provoking progressive and insidious liver damage. Among the most potent risk factors for accelerating the progression of NAFLD to fibrosis or cirrhosis, diabetes stands out. Despite the rapid rise in NAFLD rates, identifying the optimal treatment remains a challenge. Interestingly, NAFLD amelioration or remission appears to be associated with a lower risk of T2DM, indicating that liver-centric therapies could reduce the risk of developing T2DM and vice versa. Consequently, assessing NAFLD requires a multidisciplinary approach to identify and manage this multisystemic clinical entity early. With the continuously emerging new evidence, innovative therapeutic strategies are being developed for the treatment of NAFLD, prioritizing a combination of lifestyle changes and glucose-lowering medications. Based on recent evidence, this review scrutinizes all practical and sustainable interventions to achieve a resolution of NAFLD through a multimodal approach. |
format | Online Article Text |
id | pubmed-10141666 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101416662023-04-29 Therapeutic Potentials of Reducing Liver Fat in Non-Alcoholic Fatty Liver Disease: Close Association with Type 2 Diabetes Tsamos, Georgios Vasdeki, Dimitra Koufakis, Theocharis Michou, Vassiliki Makedou, Kali Tzimagiorgis, Georgios Metabolites Review Nonalcoholic fatty liver disease (NAFLD), the most widespread chronic liver disease worldwide, confers a significant burden on health systems and leads to increased mortality and morbidity through several extrahepatic complications. NAFLD comprises a broad spectrum of liver-related disorders, including steatosis, cirrhosis, and hepatocellular carcinoma. It affects almost 30% of adults in the general population and up to 70% of people with type 2 diabetes (T2DM), sharing common pathogenetic pathways with the latter. In addition, NAFLD is closely related to obesity, which acts in synergy with other predisposing conditions, including alcohol consumption, provoking progressive and insidious liver damage. Among the most potent risk factors for accelerating the progression of NAFLD to fibrosis or cirrhosis, diabetes stands out. Despite the rapid rise in NAFLD rates, identifying the optimal treatment remains a challenge. Interestingly, NAFLD amelioration or remission appears to be associated with a lower risk of T2DM, indicating that liver-centric therapies could reduce the risk of developing T2DM and vice versa. Consequently, assessing NAFLD requires a multidisciplinary approach to identify and manage this multisystemic clinical entity early. With the continuously emerging new evidence, innovative therapeutic strategies are being developed for the treatment of NAFLD, prioritizing a combination of lifestyle changes and glucose-lowering medications. Based on recent evidence, this review scrutinizes all practical and sustainable interventions to achieve a resolution of NAFLD through a multimodal approach. MDPI 2023-04-04 /pmc/articles/PMC10141666/ /pubmed/37110175 http://dx.doi.org/10.3390/metabo13040517 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Tsamos, Georgios Vasdeki, Dimitra Koufakis, Theocharis Michou, Vassiliki Makedou, Kali Tzimagiorgis, Georgios Therapeutic Potentials of Reducing Liver Fat in Non-Alcoholic Fatty Liver Disease: Close Association with Type 2 Diabetes |
title | Therapeutic Potentials of Reducing Liver Fat in Non-Alcoholic Fatty Liver Disease: Close Association with Type 2 Diabetes |
title_full | Therapeutic Potentials of Reducing Liver Fat in Non-Alcoholic Fatty Liver Disease: Close Association with Type 2 Diabetes |
title_fullStr | Therapeutic Potentials of Reducing Liver Fat in Non-Alcoholic Fatty Liver Disease: Close Association with Type 2 Diabetes |
title_full_unstemmed | Therapeutic Potentials of Reducing Liver Fat in Non-Alcoholic Fatty Liver Disease: Close Association with Type 2 Diabetes |
title_short | Therapeutic Potentials of Reducing Liver Fat in Non-Alcoholic Fatty Liver Disease: Close Association with Type 2 Diabetes |
title_sort | therapeutic potentials of reducing liver fat in non-alcoholic fatty liver disease: close association with type 2 diabetes |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141666/ https://www.ncbi.nlm.nih.gov/pubmed/37110175 http://dx.doi.org/10.3390/metabo13040517 |
work_keys_str_mv | AT tsamosgeorgios therapeuticpotentialsofreducingliverfatinnonalcoholicfattyliverdiseasecloseassociationwithtype2diabetes AT vasdekidimitra therapeuticpotentialsofreducingliverfatinnonalcoholicfattyliverdiseasecloseassociationwithtype2diabetes AT koufakistheocharis therapeuticpotentialsofreducingliverfatinnonalcoholicfattyliverdiseasecloseassociationwithtype2diabetes AT michouvassiliki therapeuticpotentialsofreducingliverfatinnonalcoholicfattyliverdiseasecloseassociationwithtype2diabetes AT makedoukali therapeuticpotentialsofreducingliverfatinnonalcoholicfattyliverdiseasecloseassociationwithtype2diabetes AT tzimagiorgisgeorgios therapeuticpotentialsofreducingliverfatinnonalcoholicfattyliverdiseasecloseassociationwithtype2diabetes |